{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:42:08Z","timestamp":1791880928795,"version":"4.3.4"},"reference-count":260,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents the most common histologic form of the disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary. Primary treatment of perianal cancer and anal canal cancer are similar and include chemoradiation in most cases. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because additional curative-intent treatment is possible. Biopsy-proven evidence of locally recurrent or persistent disease after primary treatment may require surgical treatment. Systemic therapy is generally recommended for extrapelvic metastatic disease. Recent updates to the NCCN Guidelines for Anal Carcinoma include staging classification updates based on the 9th edition of the AJCC Staging System and updates to the systemic therapy recommendations based on new data that better define optimal treatment of patients with metastatic anal carcinoma.<\/jats:p>","DOI":"10.6004\/jnccn.2023.0030","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T19:46:17Z","timestamp":1686599177000},"page":"653-677","source":"Crossref","is-referenced-by-count":99,"title":["Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"21","author":[{"given":"Al B.","family":"Benson","sequence":"first","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Al-Hawary","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilofer","family":"Azad","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jen","family":"Chen","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen K.","family":"Ciombor","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Cohen","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry S.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Deming","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garrido-Laguna","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Grem","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Randolph","family":"Hecht","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hoffe","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joleen","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Mayo Clinic Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hunt","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Hussan","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jeck","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Johung","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Joseph","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Kirilcuk","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Krishnamurthi","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Maratt","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells A.","family":"Messersmith","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Meyerhardt","sequence":"additional","affiliation":[{"name":"Dana-Farber Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Miller","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Mulcahy","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Nurkin","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Parikh","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitendra","family":"Patel","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Saltz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Schneider","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shibata","sequence":"additional","affiliation":[{"name":"The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Skibber","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos T.","family":"Sofocleous","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Stotsky-Himelfarb","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tavakkoli","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Willett","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Williams","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankie","family":"Algieri","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Gurski","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Stehman","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS,  Cancer statistics, 2023. CA Cancer J Clin 2023;73:17\u201348."},{"key":"B2","series-title":"J Natl Cancer Inst","first-page":"175","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels","volume":"105","author":"Jemal A","year":"2013","unstructured":"Jemal A, Simard EP, Dorell C,  Annual Report to the Nation on the Status of Cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175\u2013201."},{"key":"B3","series-title":"Cancer","first-page":"281","article-title":"Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973\u20132000","volume":"101","author":"Johnson LG","year":"2004","unstructured":"Johnson LG, Madeleine MM, Newcomer LM,  Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973\u20132000. Cancer 2004;101:281\u2013288."},{"key":"B4","series-title":"J Clin Oncol","first-page":"1569","article-title":"Changing patterns of anal canal carcinoma in the United States","volume":"31","author":"Nelson RA","year":"2013","unstructured":"Nelson RA, Levine AM, Bernstein L,  Changing patterns of anal canal carcinoma in the United States. J Clin Oncol 2013;31:1569\u20131575."},{"key":"B5","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"1548","article-title":"Anal cancer incidence in the United States, 1977\u20132011: distinct patterns by histology and behavior","volume":"24","author":"Shiels MS","year":"2015","unstructured":"Shiels MS, Kreimer AR, Coghill AE,  Anal cancer incidence in the United States, 1977\u20132011: distinct patterns by histology and behavior. Cancer Epidemiol Biomarkers Prev 2015;24:1548\u20131556."},{"key":"B6","series-title":"J Natl Cancer Inst","first-page":"829","article-title":"Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001\u20132015","volume":"112","author":"Deshmukh AA","year":"2020","unstructured":"Deshmukh AA, Suk R, Shiels MS,  Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001\u20132015. J Natl Cancer Inst 2020;112:829\u2013838."},{"key":"B7","article-title":"Anal squamous cell carcinoma: a growing threat to women\u2019s health and call for action","author":"Raed A","unstructured":"Raed A, Zandu M, Sharma A,  Anal squamous cell carcinoma: a growing threat to women\u2019s health and call for action. Accessed February 14, 2023. Available at: https:\/\/www.eventscribe.com\/2020\/ACG\/fsPopup.asp?efp= RElCSUFHUk02NDI2&PosterID=298982&rnd=0.3727714&mode= posterinfo"},{"key":"B8","series-title":"Radiother Oncol","first-page":"330","article-title":"Anal cancer: ESMO- ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"111","author":"Glynne-Jones R","year":"2014","unstructured":"Glynne-Jones R, Nilsson PJ, Aschele C,  Anal cancer: ESMO- ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol 2014;111:330\u2013339."},{"key":"B9","series-title":"Dig Liver Dis","first-page":"831","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto L","year":"2017","unstructured":"Moureau-Zabotto L, Vendrely V, Abramowitz L,  Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Dig Liver Dis 2017;49:831\u2013840."},{"key":"B10","series-title":"Dis Colon Rectum","first-page":"755","article-title":"The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Anal Squamous Cell Cancers (revised 2018)","volume":"61","author":"Stewart DB","year":"2018","unstructured":"Stewart DB, Gaertner WB, Glasgow SC,  The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Anal Squamous Cell Cancers (revised 2018). Dis Colon Rectum 2018;61:755\u2013774."},{"key":"B11","series-title":"Cancer","first-page":"270","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling JR","year":"2004","unstructured":"Daling JR, Madeleine MM, Johnson LG,  Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270\u2013280."},{"key":"B12","series-title":"N Engl J Med","first-page":"1350","article-title":"Sexually transmitted infection as a cause of anal cancer","volume":"337","author":"Frisch M","year":"1997","unstructured":"Frisch M, Glimelius B, van den Brule AJ,  Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997;337:1350\u20131358."},{"key":"B13","series-title":"Gynecol Oncol","first-page":"395","article-title":"Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario","volume":"114","author":"Jim\u00e9nez W","year":"2009","unstructured":"Jim\u00e9nez W, Paszat L, Kupets R,  Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol 2009;114:395\u2013398."},{"key":"B14","series-title":"N Engl J Med","first-page":"792","article-title":"Carcinoma of the anal canal","volume":"342","author":"Ryan DP","year":"2000","unstructured":"Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med 2000;342:792\u2013800."},{"key":"B15","series-title":"Int J Cancer","first-page":"675","article-title":"Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978\u20132005","volume":"127","author":"Sunesen KG","year":"2010","unstructured":"Sunesen KG, N\u00f8rgaard M, Thorlacius-Ussing O,  Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978\u20132005. Int J Cancer 2010;127:675\u2013684."},{"key":"B16","series-title":"J Natl Cancer Inst","first-page":"1500","article-title":"Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome","volume":"92","author":"Frisch M","year":"2000","unstructured":"Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500\u20131510."},{"key":"B17","series-title":"Oncologist","first-page":"524","article-title":"Anal cancer: an overview","volume":"12","author":"Uronis HE","year":"2007","unstructured":"Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist 2007;12:524\u2013534."},{"key":"B18","series-title":"Am J Transplant","first-page":"3520","article-title":"Burden of anal squamous cell carcinoma, squamous intraepithelial lesions and HPV16 infection in solid organ transplant recipients: a systematic review and meta-analysis","volume":"20","author":"Albuquerque A","year":"2020","unstructured":"Albuquerque A, Stirrup O, Nathan M,  Burden of anal squamous cell carcinoma, squamous intraepithelial lesions and HPV16 infection in solid organ transplant recipients: a systematic review and meta-analysis. Am J Transplant 2020;20:3520\u20133528."},{"key":"B19","series-title":"Int J Cancer","first-page":"38","article-title":"A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale","volume":"148","author":"Clifford GM","year":"2021","unstructured":"Clifford GM, Georges D, Shiels MS,  A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale. Int J Cancer 2021;148:38\u201347."},{"key":"B20","series-title":"Int J Cancer","first-page":"1626","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"124","author":"De Vuyst H","year":"2009","unstructured":"De Vuyst H, Clifford GM, Nascimento MC,  Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124:1626\u20131636."},{"key":"B21","series-title":"Int J Cancer","first-page":"2375","article-title":"Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions","volume":"124","author":"Hoots BE","year":"2009","unstructured":"Hoots BE, Palefsky JM, Pimenta JM,  Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124:2375\u20132383."},{"key":"B22","series-title":"Cancer Epidemiol","first-page":"807","article-title":"Squamous anal cancer: patient characteristics and HPV type distribution","volume":"37","author":"Ouhoummane N","year":"2013","unstructured":"Ouhoummane N, Steben M, Coutl\u00e9e F,  Squamous anal cancer: patient characteristics and HPV type distribution. Cancer Epidemiol 2013;37:807\u2013812."},{"key":"B23","series-title":"J Low Genit Tract Dis","first-page":"397","article-title":"Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction","volume":"17","author":"Steinau M","year":"2013","unstructured":"Steinau M, Unger ER, Hernandez BY,  Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis 2013;17:397\u2013403."},{"key":"B24","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"258","article-title":"Human papillomavirus-associated cancers - United States, 2004\u20132008","volume":"61","year":"2012","unstructured":"U.S. Centers for Disease Control and Prevention. Human papillomavirus-associated cancers - United States, 2004\u20132008. MMWR Morb Mortal Wkly Rep 2012;61:258\u2013261."},{"key":"B25","series-title":"J Infect Dis","first-page":"361","article-title":"Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men","volume":"177","author":"Palefsky JM","year":"1998","unstructured":"Palefsky JM, Holly EA, Ralston ML,  Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998;177:361\u2013367."},{"key":"B26","series-title":"Ann Intern Med","first-page":"728","article-title":"Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992\u20132003","volume":"148","author":"Patel P","year":"2008","unstructured":"Patel P, Hanson DL, Sullivan PS,  Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992\u20132003. Ann Intern Med 2008;148:728\u2013736."},{"key":"B27","series-title":"J Natl Cancer Inst","first-page":"1120","article-title":"Risk of human papillomavirus-associated cancers among persons with AIDS","volume":"101","author":"Chaturvedi AK","year":"2009","unstructured":"Chaturvedi AK, Madeleine MM, Biggar RJ,  Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009;101:1120\u20131130."},{"key":"B28","series-title":"J Clin Oncol","first-page":"68","article-title":"Anal cancer risk among people with HIV Infection in the United States","volume":"36","author":"Col\u00f3n-L\u00f3pez V","year":"2018","unstructured":"Col\u00f3n-L\u00f3pez V, Shiels MS, Machin M,  Anal cancer risk among people with HIV Infection in the United States. J Clin Oncol 2018;36:68\u201375."},{"key":"B29","series-title":"Lancet","first-page":"59","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich AE","year":"2007","unstructured":"Grulich AE, van Leeuwen MT, Falster MO,  Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59\u201367."},{"key":"B30","series-title":"Lancet HIV","first-page":"e495","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez RU","year":"2017","unstructured":"Hern\u00e1ndez-Ram\u00edrez RU, Shiels MS, Dubrow R,  Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017;4:e495\u2013504."},{"key":"B31","series-title":"Clin Infect Dis","first-page":"1026","article-title":"Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America","volume":"54","author":"Silverberg MJ","year":"2012","unstructured":"Silverberg MJ, Lau B, Justice AC,  Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012;54:1026\u20131034."},{"key":"B32","series-title":"Am J Obstet Gynecol","first-page":"278","article-title":"Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: a systematic review","volume":"213","author":"Stier EA","year":"2015","unstructured":"Stier EA, Sebring MC, Mendez AE,  Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: a systematic review. Am J Obstet Gynecol 2015;213:278\u2013309."},{"key":"B33","series-title":"J Clin Oncol","first-page":"4360","article-title":"Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French hospital database on HIV","volume":"30","author":"Piketty C","year":"2012","unstructured":"Piketty C, Selinger-Leneman H, Bouvier AM,  Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French hospital database on HIV. J Clin Oncol 2012;30:4360\u20134366."},{"key":"B34","series-title":"Sex Transm Infect","first-page":"15","article-title":"Prolonged antiretroviral therapy is associated with fewer anal high-grade squamous intraepithelial lesions in HIV-positive MSM in a cross-sectional study","volume":"93","author":"Libois A","year":"2017","unstructured":"Libois A, Feoli F, Nkuize M,  Prolonged antiretroviral therapy is associated with fewer anal high-grade squamous intraepithelial lesions in HIV-positive MSM in a cross-sectional study. Sex Transm Infect 2017;93:15\u201317."},{"key":"B35","series-title":"Int J Cancer","first-page":"1147","article-title":"Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men","volume":"134","author":"Berry JM","year":"2014","unstructured":"Berry JM, Jay N, Cranston RD,  Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. Int J Cancer 2014;134:1147\u20131155."},{"key":"B36","series-title":"Br J Surg","first-page":"1133","article-title":"Malignant transformation of high-grade anal intraepithelial neoplasia","volume":"92","author":"Scholefield JH","year":"2005","unstructured":"Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg 2005;92:1133\u20131136."},{"key":"B37","series-title":"ANZ J Surg","first-page":"715","article-title":"Malignant progression of anal intra-epithelial neoplasia","volume":"76","author":"Watson AJ","year":"2006","unstructured":"Watson AJ, Smith BB, Whitehead MR,  Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg 2006;76:715\u2013717."},{"key":"B38","series-title":"Dis Colon Rectum","first-page":"836","article-title":"Progression from perianal high-grade anal intraepithelial neoplasia to anal cancer in HIV-positive men who have sex with men","volume":"59","author":"Tinmouth J","year":"2016","unstructured":"Tinmouth J, Peeva V, Amare H,  Progression from perianal high-grade anal intraepithelial neoplasia to anal cancer in HIV-positive men who have sex with men. Dis Colon Rectum 2016;59:836\u2013842."},{"key":"B39","series-title":"Dig Liver Dis","first-page":"806","article-title":"High-grade anal intraepithelial neoplasia: progression to invasive cancer is not a certainty","volume":"48","author":"Gautier M","year":"2016","unstructured":"Gautier M, Brochard C, Lion A,  High-grade anal intraepithelial neoplasia: progression to invasive cancer is not a certainty. Dig Liver Dis 2016;48:806\u2013811."},{"key":"B40","series-title":"Dis Colon Rectum","first-page":"239","article-title":"Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia","volume":"52","author":"Berry JM","year":"2009","unstructured":"Berry JM, Palefsky JM, Jay N,  Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum 2009;52:239\u2013247."},{"key":"B41","series-title":"J Assoc Nurses AIDS Care","first-page":"465","article-title":"Elements of an anal dysplasia screening program","volume":"22","author":"Jay N","year":"2011","unstructured":"Jay N. Elements of an anal dysplasia screening program. J Assoc Nurses AIDS Care 2011;22:465\u2013477."},{"key":"B42","series-title":"J Eur Acad Dermatol Venereol","first-page":"995","article-title":"The male ScreenING Study: prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany","volume":"30","author":"Fuchs W","year":"2016","unstructured":"Fuchs W, Wieland U, Skaletz-Rorowski A,  The male ScreenING Study: prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany. J Eur Acad Dermatol Venereol 2016;30:995\u20131001."},{"key":"B43","series-title":"Cancer Cytopathol","first-page":"415","article-title":"The performance of anal cytology as a screening test for anal HSILs in homosexual men","volume":"124","author":"Jin F","year":"2016","unstructured":"Jin F, Grulich AE, Poynten IM,  The performance of anal cytology as a screening test for anal HSILs in homosexual men. Cancer Cytopathol 2016;124:415\u2013424."},{"key":"B44","series-title":"Lancet Oncol","first-page":"487","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis","volume":"13","author":"Machalek DA","year":"2012","unstructured":"Machalek DA, Poynten M, Jin F,  Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012;13:487\u2013500."},{"key":"B45","series-title":"AIDS","first-page":"1375","article-title":"A prospective study of anal cancer screening in HIV-positive and negative MSM","volume":"30","author":"Schofield AM","year":"2016","unstructured":"Schofield AM, Sadler L, Nelson L,  A prospective study of anal cancer screening in HIV-positive and negative MSM. AIDS 2016;30:1375\u20131383."},{"key":"B46","series-title":"Lancet Oncol","first-page":"e278","article-title":"Anal cancer screening","volume":"13","author":"Barroso LF","year":"2012","unstructured":"Barroso LF. Anal cancer screening. Lancet Oncol 2012;13:e278\u2013279; author reply e280."},{"key":"B47","series-title":"Dis Colon Rectum","first-page":"316","article-title":"Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer","volume":"57","author":"Goldstone SE","year":"2014","unstructured":"Goldstone SE, Johnstone AA, Moshier EL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. Dis Colon Rectum 2014;57:316\u2013323."},{"key":"B48","series-title":"Lancet Oncol","first-page":"e279","article-title":"Anal cancer screening","volume":"13","author":"Palefsky J","year":"2012","unstructured":"Palefsky J, Berry JM, Jay N. Anal cancer screening. Lancet Oncol 2012;13:e279\u2013280; author reply e280."},{"key":"B49","series-title":"Curr Infect Dis Rep","first-page":"126","article-title":"Evaluation and management of anal intraepithelial neoplasia in HIV-negative and HIV-positive men who have sex with men","volume":"12","author":"Park IU","year":"2010","unstructured":"Park IU, Palefsky JM. Evaluation and management of anal intraepithelial neoplasia in HIV-negative and HIV-positive men who have sex with men. Curr Infect Dis Rep 2010;12:126\u2013133."},{"key":"B50","series-title":"J Assoc Nurses AIDS Care","first-page":"433","article-title":"The need for anal dysplasia screening and treatment programs for HIV-infected men who have sex with men: a review of the literature","volume":"22","author":"Roark R","year":"2011","unstructured":"Roark R. The need for anal dysplasia screening and treatment programs for HIV-infected men who have sex with men: a review of the literature. J Assoc Nurses AIDS Care 2011;22:433\u2013443."},{"key":"B51","series-title":"Colorectal Dis","first-page":"3","article-title":"Guidelines for management of anal intraepithelial neoplasia","volume":"13","author":"Scholefield JH","year":"2011","unstructured":"Scholefield JH, Harris D, Radcliffe A. Guidelines for management of anal intraepithelial neoplasia. Colorectal Dis 2011;13(Suppl_1):3\u201310."},{"key":"B52","series-title":"Lancet Oncol","first-page":"438","article-title":"Screening for anal cancer: endpoints needed","volume":"13","author":"Wentzensen N","year":"2012","unstructured":"Wentzensen N. Screening for anal cancer: endpoints needed. Lancet Oncol 2012;13:438\u2013440."},{"key":"B53","series-title":"Diagn Cytopathol","first-page":"307","article-title":"Predictive value of the anal cytology for detecting anal intraepithelial neoplasia or worse: a systematic review and meta-analysis","volume":"47","author":"Chen CC","year":"2019","unstructured":"Chen CC, Chou YY. Predictive value of the anal cytology for detecting anal intraepithelial neoplasia or worse: a systematic review and meta-analysis. Diagn Cytopathol 2019;47:307\u2013314."},{"key":"B54","series-title":"Open Forum Infect Dis","first-page":"ofz191","article-title":"The accuracy of anal swab-based tests to detect high-grade anal intraepithelial neoplasia in HIV-infected patients: a systematic review and meta-analysis","volume":"6","author":"Dias Gon\u00e7alves Lima F","year":"2019","unstructured":"Dias Gon\u00e7alves Lima F, Viset JD, Leeflang MMG,  The accuracy of anal swab-based tests to detect high-grade anal intraepithelial neoplasia in HIV-infected patients: a systematic review and meta-analysis. Open Forum Infect Dis 2019;6:ofz191."},{"key":"B55","series-title":"Dis Colon Rectum","first-page":"112","article-title":"Accuracy of anal cytology for diagnostic of precursor lesions of anal cancer: systematic review and meta-analysis","volume":"62","author":"Gon\u00e7alves JCN","year":"2019","unstructured":"Gon\u00e7alves JCN, Macedo ACL, Madeira K,  Accuracy of anal cytology for diagnostic of precursor lesions of anal cancer: systematic review and meta-analysis. Dis Colon Rectum 2019;62:112\u2013120."},{"key":"B56","series-title":"Dis Colon Rectum","first-page":"735","article-title":"Practice parameters for anal squamous neoplasms","volume":"55","author":"Steele SR","year":"2012","unstructured":"Steele SR, Varma MG, Melton GB,  Practice parameters for anal squamous neoplasms. Dis Colon Rectum 2012;55:735\u2013749."},{"key":"B57","series-title":"BMC Cancer","first-page":"557","article-title":"Regional and national guideline recommendations for digital ano-rectal examination as a means for anal cancer screening in HIV positive men who have sex with men: a systematic review","volume":"14","author":"Ong JJ","year":"2014","unstructured":"Ong JJ, Chen M, Grulich AE,  Regional and national guideline recommendations for digital ano-rectal examination as a means for anal cancer screening in HIV positive men who have sex with men: a systematic review. BMC Cancer 2014;14:557."},{"key":"B58","series-title":"Colorectal Dis","first-page":"135","article-title":"Systematic review of guidelines for the assessment and management of high-grade anal intraepithelial neoplasia (AIN II\/III)","volume":"18","author":"Alam NN","year":"2016","unstructured":"Alam NN, White DA, Narang SK,  Systematic review of guidelines for the assessment and management of high-grade anal intraepithelial neoplasia (AIN II\/III). Colorectal Dis 2016;18:135\u2013146."},{"key":"B59","series-title":"J Dtsch Dermatol Ges","first-page":"256","article-title":"S1 guideline: anal intraepithelial neoplasia (AIN) and perianal intraepithelial neoplasia (PAIN)","volume":"9","author":"Hartschuh W","year":"2011","unstructured":"Hartschuh W, Breitkopf C, Lenhard B,  S1 guideline: anal intraepithelial neoplasia (AIN) and perianal intraepithelial neoplasia (PAIN). J Dtsch Dermatol Ges 2011;9:256\u2013258."},{"key":"B60","series-title":"Lancet Oncol","first-page":"346","article-title":"Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial","volume":"14","author":"Richel O","year":"2013","unstructured":"Richel O, de Vries HJ, van Noesel CJ,  Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol 2013;14:346\u2013353."},{"key":"B61","series-title":"N Engl J Med","first-page":"2273","article-title":"Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer","volume":"386","author":"Palefsky JM","year":"2022","unstructured":"Palefsky JM, Lee JY, Jay N,  Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. N Engl J Med 2022;386:2273\u20132282."},{"key":"B62","series-title":"N Engl J Med","first-page":"1915","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Villa LL","year":"2007","unstructured":"Villa LL, Perez G, Kjaer SK,  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915\u20131927."},{"key":"B63","series-title":"BMJ","first-page":"c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Dillner J","year":"2010","unstructured":"Dillner J, Kjaer SK, Wheeler CM,  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493."},{"key":"B64","series-title":"N Engl J Med","first-page":"1928","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland SM","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM,  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928\u20131943."},{"key":"B65","series-title":"N Engl J Med","first-page":"401","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano AR","year":"2011","unstructured":"Giuliano AR, Palefsky JM, Goldstone S,  Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011;364:401\u2013411."},{"key":"B66","series-title":"N Engl J Med","first-page":"1576","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky JM","year":"2011","unstructured":"Palefsky JM, Giuliano AR, Goldstone S,  HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576\u20131585."},{"key":"B67","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","year":"2010","unstructured":"U.S. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626\u2013629."},{"key":"B68","series-title":"Lancet Oncol","first-page":"862","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer AR","year":"2011","unstructured":"Kreimer AR, Gonz\u00e1lez P, Katki HA,  Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011;12:862\u2013870."},{"key":"B69","series-title":"J Natl Cancer Inst","first-page":"djv302","article-title":"Multisite HPV16\/18 vaccine efficacy against cervical, anal, and oral HPV infection","volume":"108","author":"Beachler DC","year":"2015","unstructured":"Beachler DC, Kreimer AR, Schiffman M,  Multisite HPV16\/18 vaccine efficacy against cervical, anal, and oral HPV infection. J Natl Cancer Inst 2015;108:djv302."},{"key":"B70","series-title":"Lancet Oncol","first-page":"89","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen M","year":"2012","unstructured":"Lehtinen M, Paavonen J, Wheeler CM,  Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89\u201399."},{"key":"B71","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky E","year":"2015","unstructured":"Petrosky E, Bocchini JA Jr, Hariri S,  Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015;64:300\u2013304."},{"key":"B72","series-title":"J Natl Cancer Inst","first-page":"djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya M","year":"2015","unstructured":"Saraiya M, Unger ER, Thompson TD,  US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst 2015;107:djv086."},{"key":"B73","series-title":"N Engl J Med","first-page":"711","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura EA","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE,  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711\u2013723."},{"key":"B74","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz LE","year":"2014","unstructured":"Markowitz LE, Dunne EF, Saraiya M,  Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014;63:1\u201330."},{"key":"B75","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"1405","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites E","year":"2016","unstructured":"Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2016;65:1405\u20131408."},{"key":"B76","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"136","article-title":"Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2017","volume":"66","author":"Kim DK","year":"2017","unstructured":"Kim DK, Riley LE, Harriman KH,  Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2017. MMWR Morb Mortal Wkly Rep 2017;66:136\u2013138."},{"key":"B77","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"698","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Meites E","year":"2019","unstructured":"Meites E, Szilagyi PG, Chesson HW,  Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019;68:698\u2013702."},{"key":"B78","series-title":"Pediatrics","first-page":"602","article-title":"HPV vaccine recommendations","volume":"129","author":"Brady MT","year":"2012","unstructured":"Brady MT, Byington CL, Davies D,  HPV vaccine recommendations. Pediatrics 2012;129:602\u2013605."},{"key":"B79","series-title":"J Clin Oncol","first-page":"1803","article-title":"American Society of Clinical Oncology statement: human papillomavirus vaccination for cancer prevention","volume":"34","author":"Bailey HH","year":"2016","unstructured":"Bailey HH, Chuang LT, duPont NC,  American Society of Clinical Oncology statement: human papillomavirus vaccination for cancer prevention. J Clin Oncol 2016;34:1803\u20131812."},{"key":"B80","article-title":"FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old","unstructured":"U.S. Food & Drug Administration. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. Accessed February 14, 2023. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old"},{"key":"B81","series-title":"AJCC Cancer Staging System: Anus","author":"Goodman KA","year":"2022","unstructured":"Goodman KA, Gollub M, Eng C,  AJCC Cancer Staging System: Anus. 9th Version. American College of Surgeons; 2022."},{"key":"B82","series-title":"Cancer: Principles & Practice of Oncology","first-page":"1301","article-title":"Cancer of the anal region","author":"Cummings BJ","year":"2008","unstructured":"Cummings BJ, Swallow CJ, Ajani JA. Cancer of the anal region. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, et al, eds. Cancer: Principles & Practice of Oncology. 8th ed. Lippincott, Williams & Wilkins; 2008:1301\u20131314."},{"key":"B83","series-title":"Sex Health","first-page":"513","article-title":"Anal anatomy and normal histology","volume":"9","author":"Pandey P","year":"2012","unstructured":"Pandey P. Anal anatomy and normal histology. Sex Health 2012;9:513\u2013516."},{"key":"B84","series-title":"Dis Colon Rectum","first-page":"600","article-title":"The length of the anal canal","volume":"24","author":"Nivatvongs S","year":"1981","unstructured":"Nivatvongs S, Stern HS, Fryd DS. The length of the anal canal. Dis Colon Rectum 1981;24:600\u2013601."},{"key":"B85","series-title":"Histological Typing of Intestinal Tumours","author":"Jass JR","year":"1989","unstructured":"Jass JR, Sobin LH. Histological Typing of Intestinal Tumours. Springer Berlin; 1989."},{"key":"B86","series-title":"WHO Classification of Tumours, Volume 2: Pathology and Genetics of Tumours of the Digestive System","first-page":"145","article-title":"Tumours of the anal canal","author":"Fenger C","year":"2000","unstructured":"Fenger C, Frisch M, Marti MC,  Tumours of the anal canal. In: Hamilton SR, Aaltonen LA, eds. WHO Classification of Tumours, Volume 2: Pathology and Genetics of Tumours of the Digestive System. 3rd ed. IARC Press; 2000:145\u2013155."},{"key":"B87","series-title":"WHO Classification of Tumours of the Digestive System","first-page":"183","article-title":"Tumours of the anal canal","author":"Welton ML","year":"2010","unstructured":"Welton ML, Lambert R, Bosman FT. Tumours of the anal canal. In: Bosman FT, Carneiro F, Hruban RH, et al, eds. WHO Classification of Tumours of the Digestive System. 4th ed. IARC Press; 2010:183."},{"key":"B88","series-title":"Pathology","first-page":"573","article-title":"Prognostic factors in anal carcinoma","volume":"34","author":"Fenger C","year":"2002","unstructured":"Fenger C. Prognostic factors in anal carcinoma. Pathology 2002;34:573\u2013578."},{"key":"B89","series-title":"Surg Clin North Am","first-page":"1475","article-title":"Neoplasms of the anus","volume":"74","author":"Oliver GC","year":"1994","unstructured":"Oliver GC, Labow SB. Neoplasms of the anus. Surg Clin North Am 1994;74:1475\u20131490."},{"key":"B90","article-title":"Protocol for the examination of excision specimens from patients with carcinoma of the anus","author":"Burgart LJ","unstructured":"Burgart LJ, Kakar S, Shi C,  Protocol for the examination of excision specimens from patients with carcinoma of the anus. Accessed February 14, 2023. Available at: https:\/\/documents.cap.org\/protocols\/cp-gilower-anus-excision-20-4101.pdf"},{"key":"B91","article-title":"Protocol for the Examination of resection specimens from patients with carcinoma of the anus","author":"Burgart LJ","unstructured":"Burgart LJ, Shi C, Driman DK,  Protocol for the Examination of resection specimens from patients with carcinoma of the anus. Accessed February 14, 2023. Available at: https:\/\/documents.cap.org\/protocols\/cp-gilower-colonrectum-resection-20-4100.pdf"},{"key":"B92","series-title":"AJCC Cancer Staging Manual","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. 7th ed. Springer; 2010."},{"key":"B93","series-title":"SEER cancer statistics review, 1975\u20132007","unstructured":"Altekruse SF, Kosary CL, Krapcho M, et al, eds. SEER cancer statistics review, 1975\u20132007. Accessed February 14, 2023. Available at: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2007\/"},{"key":"B94","series-title":"Cancer","first-page":"77","article-title":"Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature","volume":"92","author":"Gerard JP","year":"2001","unstructured":"Gerard JP, Chapet O, Samiei F,  Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. Cancer 2001;92:77\u201384."},{"key":"B95","series-title":"Int J Radiat Oncol Biol Phys","first-page":"638","article-title":"Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial","volume":"87","author":"Gunderson LL","year":"2013","unstructured":"Gunderson LL, Moughan J, Ajani JA,  Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys 2013;87:638\u2013645."},{"key":"B96","series-title":"AJCC Cancer Staging Manual","first-page":"275","article-title":"Anus","author":"Welton ML","year":"2017","unstructured":"Welton ML, Steele SR, Goodman KA,  Anus. In: Amin MB, Greene FL, Edge SB, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017:275\u2013286."},{"key":"B97","series-title":"Surg Gynecol Obstet","first-page":"238","article-title":"Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique","volume":"169","author":"Wade DS","year":"1989","unstructured":"Wade DS, Herrera L, Castillo NB,  Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique. Surg Gynecol Obstet 1989;169:238\u2013242."},{"key":"B98","series-title":"JAMA","first-page":"1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani JA","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL,  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914\u20131921."},{"key":"B99","series-title":"J Clin Oncol","first-page":"1116","article-title":"US intergroup anal carcinoma trial: tumor diameter predicts for colostomy","volume":"27","author":"Ajani JA","year":"2009","unstructured":"Ajani JA, Winter KA, Gunderson LL,  US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol 2009;27:1116\u20131121."},{"key":"B100","series-title":"J Clin Oncol","first-page":"2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups","volume":"15","author":"Bartelink H","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F,  Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040\u20132049."},{"key":"B101","series-title":"Cancer","first-page":"748","article-title":"Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I)","volume":"119","author":"Glynne-Jones R","year":"2013","unstructured":"Glynne-Jones R, Sebag-Montefiore D, Adams R,  Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer 2013;119:748\u2013755."},{"key":"B102","series-title":"Int J Cancer","first-page":"278","article-title":"Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy","volume":"136","author":"R\u00f6del F","year":"2015","unstructured":"R\u00f6del F, Wieland U, Fraunholz I,  Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Int J Cancer 2015;136:278\u2013288."},{"key":"B103","series-title":"J Clin Oncol","first-page":"1812","article-title":"Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal","volume":"32","author":"Serup-Hansen E","year":"2014","unstructured":"Serup-Hansen E, Linnemann D, Skovrider-Ruminski W,  Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol 2014;32:1812\u20131817."},{"key":"B104","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"703","article-title":"Prognostic significance of HPV DNA and p16INK4a in anal cancer: a systematic review and meta-analysis","volume":"29","author":"Urbute A","year":"2020","unstructured":"Urbute A, Rasmussen CL, Belmonte F,  Prognostic significance of HPV DNA and p16INK4a in anal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2020;29:703\u2013710."},{"key":"B105","series-title":"Clin Oncol (R Coll Radiol)","first-page":"e1","article-title":"A systematic review and meta-analysis of prognostic biomarkers in anal squamous cell carcinoma treated with primary chemoradiotherapy","volume":"31","author":"Parwaiz I","year":"2019","unstructured":"Parwaiz I, MacCabe TA, Thomas MG,  A systematic review and meta-analysis of prognostic biomarkers in anal squamous cell carcinoma treated with primary chemoradiotherapy. Clin Oncol (R Coll Radiol) 2019;31:e1\u201313."},{"key":"B106","article-title":"U.S. Statistics","unstructured":"HIV.gov. U.S. Statistics. Accessed February 14, 2023. Available at: https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics"},{"key":"B107","series-title":"J Acquir Immune Defic Syndr","first-page":"446","article-title":"Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs","volume":"39","author":"Marks G","year":"2005","unstructured":"Marks G, Crepaz N, Senterfitt JW,  Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005;39:446\u2013453."},{"key":"B108","series-title":"JAMA","first-page":"334","article-title":"Time for oncologists to opt in for routine opt-out HIV testing?","volume":"304","author":"Chiao EY","year":"2010","unstructured":"Chiao EY, Dezube BJ, Krown SE,  Time for oncologists to opt in for routine opt-out HIV testing? JAMA 2010;304:334\u2013339."},{"key":"B109","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings","volume":"55","author":"Branson BM","year":"2006","unstructured":"Branson BM, Handsfield HH, Lampe MA,  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:1\u201317; quiz CE1\u20134."},{"key":"B110","series-title":"Ann Oncol","first-page":"2078","article-title":"To PET or not to PET? That is the question. Staging in anal cancer","volume":"23","author":"Bhuva NJ","year":"2012","unstructured":"Bhuva NJ, Glynne-Jones R, Sonoda L,  To PET or not to PET? That is the question. Staging in anal cancer. Ann Oncol 2012;23:2078\u20132082."},{"key":"B111","series-title":"ScientificWorldJournal","first-page":"196068","article-title":"Diagnostic performance of positron emission tomography\/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis","volume":"2014","author":"Caldarella C","year":"2014","unstructured":"Caldarella C, Annunziata S, Treglia G,  Diagnostic performance of positron emission tomography\/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. ScientificWorldJournal 2014;2014:196068."},{"key":"B112","series-title":"Int J Radiat Oncol Biol Phys","first-page":"720","article-title":"FDG-PET\/CT in the evaluation of anal carcinoma","volume":"65","author":"Cotter SE","year":"2006","unstructured":"Cotter SE, Grigsby PW, Siegel BA,  FDG-PET\/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006;65:720\u2013725."},{"key":"B113","series-title":"Int J Radiat Oncol Biol Phys","first-page":"66","article-title":"Role of positron emission tomography-computed tomography in the management of anal cancer","volume":"84","author":"Mistrangelo M","year":"2012","unstructured":"Mistrangelo M, Pelosi E, Bell\u00f2 M,  Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys 2012;84:66\u201372."},{"key":"B114","series-title":"J Natl Compr Canc Netw","first-page":"123","article-title":"Radiation therapy advances for treatment of anal cancer","volume":"8","author":"Pepek JM","year":"2010","unstructured":"Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw 2010;8:123\u2013129."},{"key":"B115","series-title":"Mol Imaging Biol","first-page":"309","article-title":"Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal","volume":"7","author":"Trautmann TG","year":"2005","unstructured":"Trautmann TG, Zuger JH. Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005;7:309\u2013313."},{"key":"B116","series-title":"Br J Radiol","first-page":"20170370","article-title":"PET imaging in anal canal cancer: a systematic review and meta-analysis","volume":"90","author":"Mahmud A","year":"2017","unstructured":"Mahmud A, Poon R, Jonker D. PET imaging in anal canal cancer: a systematic review and meta-analysis. Br J Radiol 2017;90:20170370."},{"key":"B117","series-title":"Ann Surg Oncol","first-page":"3574","article-title":"The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis","volume":"22","author":"Jones M","year":"2015","unstructured":"Jones M, Hruby G, Solomon M,  The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2015;22:3574\u20133581."},{"key":"B118","series-title":"Crit Rev Oncol Hematol","first-page":"6","article-title":"Positron emission tomography and computed tomographic (PET\/CT) imaging for radiation therapy planning in anal cancer: a systematic review and meta-analysis","volume":"126","author":"Albertsson P","year":"2018","unstructured":"Albertsson P, Alverbratt C, Liljegren A,  Positron emission tomography and computed tomographic (PET\/CT) imaging for radiation therapy planning in anal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2018;126:6\u201312."},{"key":"B119","series-title":"Lancet Oncol","first-page":"1348","article-title":"Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study","volume":"18","author":"Sekhar H","year":"2017","unstructured":"Sekhar H, Zwahlen M, Trelle S,  Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study. Lancet Oncol 2017;18:1348\u20131359."},{"key":"B120","series-title":"Dis Colon Rectum","first-page":"354","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro ND","year":"1974","unstructured":"Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974;17:354\u2013356."},{"key":"B121","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1115","article-title":"Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C","volume":"21","author":"Cummings BJ","year":"1991","unstructured":"Cummings BJ, Keane TJ, O\u2019Sullivan B,  Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991;21:1115\u20131125."},{"key":"B122","series-title":"Dis Colon Rectum","first-page":"422","article-title":"Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients","volume":"35","author":"Papillon J","year":"1992","unstructured":"Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients. Dis Colon Rectum 1992;35:422\u2013429."},{"key":"B123","series-title":"Curr Oncol Rep","first-page":"186","article-title":"Current management of anal canal cancer","volume":"11","author":"Czito BG","year":"2009","unstructured":"Czito BG, Willett CG. Current management of anal canal cancer. Curr Oncol Rep 2009;11:186\u2013192."},{"key":"B124","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1290","article-title":"Anal cancer: an examination of radiotherapy strategies","volume":"79","author":"Glynne-Jones R","year":"2011","unstructured":"Glynne-Jones R, Lim F. Anal cancer: an examination of radiotherapy strategies. Int J Radiat Oncol Biol Phys 2011;79:1290\u20131301."},{"key":"B125","series-title":"Lancet","first-page":"1049","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin","volume":"348","year":"1996","unstructured":"UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996;348:1049\u20131054."},{"key":"B126","series-title":"Br J Cancer","first-page":"1123","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover J","year":"2010","unstructured":"Northover J, Glynne-Jones R, Sebag-Montefiore D,  Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010;102:1123\u20131128."},{"key":"B127","series-title":"Int J Colorectal Dis","first-page":"1111","article-title":"Radiotherapy alone versus chemoradiotherapy for stage I anal squamous cell carcinoma: a systematic review and meta-analysis","volume":"36","author":"Talwar G","year":"2021","unstructured":"Talwar G, Daniel R, McKechnie T,  Radiotherapy alone versus chemoradiotherapy for stage I anal squamous cell carcinoma: a systematic review and meta-analysis. Int J Colorectal Dis 2021;36:1111\u20131122."},{"key":"B128","series-title":"Dis Colon Rectum","first-page":"787","article-title":"A population-based cohort analysis of chemoradiation versus radiation alone for definitive treatment of stage I anal cancer in older patients","volume":"61","author":"Buckstein M","year":"2018","unstructured":"Buckstein M, Arens Y, Wisnivesky J,  A population-based cohort analysis of chemoradiation versus radiation alone for definitive treatment of stage I anal cancer in older patients. Dis Colon Rectum 2018;61:787\u2013794."},{"key":"B129","series-title":"Dis Colon Rectum","first-page":"43","article-title":"Combining cisplatin and mitomycin with radiotherapy in anal carcinoma","volume":"50","author":"Crehange G","year":"2007","unstructured":"Crehange G, Bosset M, Lorchel F,  Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum 2007;50:43\u201349."},{"key":"B130","series-title":"J Clin Oncol","first-page":"2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam M","year":"1996","unstructured":"Flam M, John M, Pajak TF,  Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527\u20132539."},{"key":"B131","series-title":"J Radiat Res (Tokyo)","first-page":"154","article-title":"A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial)","volume":"64","author":"Murofushi KN","year":"2023","unstructured":"Murofushi KN, Itasaka S, Shimokawa M,  A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial). J Radiat Res (Tokyo) 2023;64:154\u2013161."},{"key":"B132","series-title":"Lancet Oncol","first-page":"579","article-title":"Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial","volume":"13","author":"Hofheinz RD","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S,  Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579\u2013588."},{"key":"B133","series-title":"J Clin Oncol","first-page":"1927","article-title":"Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04","volume":"32","author":"O\u2019Connell MJ","year":"2014","unstructured":"O\u2019Connell MJ, Colangelo LH, Beart RW,  Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014;32:1927\u20131934."},{"key":"B134","series-title":"Ann Oncol","first-page":"1190","article-title":"Capecitabine versus 5-fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy","volume":"23","author":"Twelves C","year":"2012","unstructured":"Twelves C, Scheithauer W, McKendrick J,  Capecitabine versus 5-fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012;23:1190\u20131197."},{"key":"B135","series-title":"N Engl J Med","first-page":"2696","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves C","year":"2005","unstructured":"Twelves C, Wong A, Nowacki MP,  Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696\u20132704."},{"key":"B136","series-title":"Int J Radiat Oncol Biol Phys","first-page":"119","article-title":"EXTRA\u2014a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer","volume":"72","author":"Glynne-Jones R","year":"2008","unstructured":"Glynne-Jones R, Meadows H, Wan S,  EXTRA\u2014a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 2008;72:119\u2013126."},{"key":"B137","series-title":"Int J Radiat Oncol Biol Phys","first-page":"S32","article-title":"Capecitabine plus mitomycin in patients undergoing definitive chemoradiation for anal squamous cell carcinoma","volume":"90","author":"Goodman KA","year":"2014","unstructured":"Goodman KA, Rothenstein D, Lajhem C,  Capecitabine plus mitomycin in patients undergoing definitive chemoradiation for anal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2014;90(Suppl):S32\u201333."},{"key":"B138","series-title":"Br J Cancer","first-page":"1726","article-title":"Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option","volume":"111","author":"Meulendijks D","year":"2014","unstructured":"Meulendijks D, Dewit L, Tomasoa NB,  Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 2014;111:1726\u20131733."},{"key":"B139","series-title":"Radiat Oncol","first-page":"124","article-title":"Chemoradiation with capecitabine and mitomycin-C for stage I\u2013III anal squamous cell carcinoma","volume":"9","author":"Thind G","year":"2014","unstructured":"Thind G, Johal B, Follwell M,  Chemoradiation with capecitabine and mitomycin-C for stage I\u2013III anal squamous cell carcinoma. Radiat Oncol 2014;9:124."},{"key":"B140","series-title":"J Gastrointest Cancer","first-page":"75","article-title":"Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal","volume":"47","author":"Oliveira SC","year":"2016","unstructured":"Oliveira SC, Moniz CM, Riechelmann R,  Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. J Gastrointest Cancer 2016;47:75\u201381."},{"key":"B141","series-title":"Lancet Oncol","first-page":"516","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James RD","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM,  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial. Lancet Oncol 2013;14:516\u2013524."},{"key":"B142","series-title":"J Clin Oncol","first-page":"4344","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson LL","year":"2012","unstructured":"Gunderson LL, Winter KA, Ajani JA,  Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin. J Clin Oncol 2012;30:4344\u20134351."},{"key":"B143","series-title":"Nat Clin Pract Gastroenterol Hepatol","first-page":"16","article-title":"Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal?","volume":"6","author":"Eng C","year":"2009","unstructured":"Eng C, Crane CH, Rodriguez-Bigas MA. Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal? Nat Clin Pract Gastroenterol Hepatol 2009;6:16\u201317."},{"key":"B144","series-title":"Oncology (Williston Park)","first-page":"417","article-title":"Management of anal cancer in 2010. Part 2: current treatment standards and future directions","volume":"24","author":"Abbas A","year":"2010","unstructured":"Abbas A, Yang G, Fakih M. Management of anal cancer in 2010. Part 2: current treatment standards and future directions. Oncology (Williston Park) 2010;24:417\u2013424."},{"key":"B145","series-title":"J Clin Oncol","first-page":"1941","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert D","year":"2012","unstructured":"Peiffert D, Tournier-Rangeard L, G\u00e9rard JP,  Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012;30:1941\u20131948."},{"key":"B146","series-title":"Clin Oncol (R Coll Radiol)","first-page":"473","article-title":"Chemoradiotherapy for squamous cell cancer of the anal canal: a systematic review","volume":"26","author":"Spithoff K","year":"2014","unstructured":"Spithoff K, Cummings B, Jonker D,  Chemoradiotherapy for squamous cell cancer of the anal canal: a systematic review. Clin Oncol (R Coll Radiol) 2014;26:473\u2013487."},{"key":"B147","series-title":"J Surg Oncol","first-page":"66","article-title":"Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma?","volume":"104","author":"Moureau-Zabotto L","year":"2011","unstructured":"Moureau-Zabotto L, Viret F, Giovaninni M,  Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma? J Surg Oncol 2011;104:66\u201371."},{"key":"B148","series-title":"Radiother Oncol","first-page":"155","article-title":"Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin","volume":"104","author":"Sebag-Montefiore D","year":"2012","unstructured":"Sebag-Montefiore D, Meadows HM, Cunningham D,  Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. Radiother Oncol 2012;104:155\u2013160."},{"key":"B149","series-title":"Clin Colorectal Cancer","first-page":"301","article-title":"A phase II study of capecitabine\/oxaliplatin with concurrent radiotherapy in locally advanced squamous cell carcinoma of the anal canal","volume":"18","author":"Eng C","year":"2019","unstructured":"Eng C, J\u00e1come AA, Das P,  A phase II study of capecitabine\/oxaliplatin with concurrent radiotherapy in locally advanced squamous cell carcinoma of the anal canal. Clin Colorectal Cancer 2019;18:301\u2013306."},{"key":"B150","article-title":"Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer","author":"Rajdev L","unstructured":"Rajdev L. Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer. ClinicalTrials.gov identifier: NCT03233711. Accessed February 14, 2023. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03233711"},{"key":"B151","article-title":"Prescribing Information for cetuximab injection, for intravenous use","year":"2021","unstructured":"Prescribing Information for cetuximab injection, for intravenous use. 2021. Accessed February 14, 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125084s279lbl.pdf"},{"key":"B152","series-title":"BMC Cancer","first-page":"189","article-title":"Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas","volume":"10","author":"Van Damme N","year":"2010","unstructured":"Van Damme N, Deron P, Van Roy N,  Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010;10:189."},{"key":"B153","series-title":"Cancer Chemother Pharmacol","first-page":"197","article-title":"K-ras status in squamous cell anal carcinoma (SCC): it\u2019s time for target-oriented treatment?","volume":"65","author":"Zampino MG","year":"2009","unstructured":"Zampino MG, Magni E, Sonzogni A,  K-ras status in squamous cell anal carcinoma (SCC): it\u2019s time for target-oriented treatment? Cancer Chemother Pharmacol 2009;65:197\u2013199."},{"key":"B154","series-title":"J Clin Oncol","first-page":"718","article-title":"Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial (E3205)","volume":"35","author":"Garg MK","year":"2017","unstructured":"Garg MK, Zhao F, Sparano JA,  Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial (E3205). J Clin Oncol 2017;35:718\u2013726."},{"key":"B155","series-title":"J Clin Oncol","first-page":"727","article-title":"Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS Malignancy Consortium trial","volume":"35","author":"Sparano JA","year":"2017","unstructured":"Sparano JA, Lee JY, Palefsky J,  Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS Malignancy Consortium trial. J Clin Oncol 2017;35:727\u2013733."},{"key":"B156","series-title":"Cancer","first-page":"2973","article-title":"Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma","volume":"119","author":"Olivatto LO","year":"2013","unstructured":"Olivatto LO, Vieira FM, Pereira BV,  Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer 2013;119:2973\u20132980."},{"key":"B157","series-title":"Ann Oncol","first-page":"2834","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial","volume":"24","author":"Deutsch E","year":"2013","unstructured":"Deutsch E, Lemanski C, Pignon JP,  Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol 2013;24:2834\u20132838."},{"key":"B158","series-title":"Radiother Oncol","first-page":"415","article-title":"Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial","volume":"114","author":"Levy A","year":"2015","unstructured":"Levy A, Azria D, Pignon JP,  Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. Radiother Oncol 2015;114:415\u2013416."},{"key":"B159","series-title":"Oncologist","first-page":"40","article-title":"Definitive intensity-modulated chemoradiation for anal squamous cell carcinoma: outcomes and toxicity of 428 patients treated at a single institution","volume":"27","author":"Holliday EB","year":"2022","unstructured":"Holliday EB, Morris VK, Johnson B,  Definitive intensity-modulated chemoradiation for anal squamous cell carcinoma: outcomes and toxicity of 428 patients treated at a single institution. Oncologist 2022;27:40\u201347."},{"key":"B160","series-title":"Pract Radiat Oncol","first-page":"193","article-title":"Preparing patients for sexual dysfunction after radiation for anorectal cancers: a systematic review","volume":"11","author":"Wallington DG","year":"2021","unstructured":"Wallington DG, Holliday EB. Preparing patients for sexual dysfunction after radiation for anorectal cancers: a systematic review. Pract Radiat Oncol 2021;11:193\u2013201."},{"key":"B161","series-title":"Int J Radiat Oncol Biol Phys","first-page":"479","article-title":"Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy","volume":"62","author":"Ortholan C","year":"2005","unstructured":"Ortholan C, Ramaioli A, Peiffert D,  Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:479\u2013485."},{"key":"B162","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1136","article-title":"Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness","volume":"61","author":"Ferrigno R","year":"2005","unstructured":"Ferrigno R, Nakamura RA, Dos Santos Novaes PE,  Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys 2005;61:1136\u20131142."},{"key":"B163","series-title":"World J Gastroenterol","first-page":"895","article-title":"Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal","volume":"13","author":"Huang K","year":"2007","unstructured":"Huang K, Haas-Kogan D, Weinberg V,  Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 2007;13:895\u2013900."},{"key":"B164","series-title":"Cancer J Sci Am","first-page":"205","article-title":"Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08","volume":"2","author":"John M","year":"1996","unstructured":"John M, Pajak T, Flam M,  Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996;2:205\u2013211."},{"key":"B165","article-title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","unstructured":"ECOG-ACRIN Cancer Research Group. Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study. ClinicalTrials.gov identifier: NCT04166318. Accessed February 14, 2023. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04166318"},{"key":"B166","series-title":"Int J Radiat Oncol Biol Phys","first-page":"114","article-title":"Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08","volume":"72","author":"Konski A","year":"2008","unstructured":"Konski A, Garcia M Jr, John M,  Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008;72:114\u2013118."},{"key":"B167","series-title":"Ann Oncol","first-page":"1376","article-title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial","volume":"31","author":"Glynne-Jones R","year":"2020","unstructured":"Glynne-Jones R, Meadows HM, Lopes A,  Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. Ann Oncol 2020;31:1376\u20131385."},{"key":"B168","series-title":"J Clin Oncol","first-page":"5061","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11","volume":"28","author":"Ben-Josef E","year":"2010","unstructured":"Ben-Josef E, Moughan J, Ajani JA,  Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010;28:5061\u20135066."},{"key":"B169","series-title":"Oncology","first-page":"14","article-title":"Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy","volume":"65","author":"Graf R","year":"2003","unstructured":"Graf R, Wust P, Hildebrandt B,  Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 2003;65:14\u201322."},{"key":"B170","series-title":"Dis Colon Rectum","first-page":"147","article-title":"Squamous-cell carcinoma of the anal canal: predictors of treatment outcome","volume":"51","author":"Roohipour R","year":"2008","unstructured":"Roohipour R, Patil S, Goodman KA,  Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 2008;51:147\u2013153."},{"key":"B171","series-title":"Br J Cancer","first-page":"1588","article-title":"Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy","volume":"80","author":"Allal AS","year":"1999","unstructured":"Allal AS, Sprangers MA, Laurencet F,  Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer 1999;80:1588\u20131594."},{"key":"B172","series-title":"Ann Surg Oncol","first-page":"100","article-title":"High risk of colostomy with primary radiotherapy for anal cancer","volume":"14","author":"de Bree E","year":"2007","unstructured":"de Bree E, van Ruth S, Dewit LG,  High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol 2007;14:100\u2013108."},{"key":"B173","series-title":"JAMA","first-page":"2587","article-title":"Risk of pelvic fractures in older women following pelvic irradiation","volume":"294","author":"Baxter NN","year":"2005","unstructured":"Baxter NN, Habermann EB, Tepper JE,  Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005;294:2587\u20132593."},{"key":"B174","series-title":"Am J Clin Oncol","first-page":"8","article-title":"Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study","volume":"39","author":"Call JA","year":"2016","unstructured":"Call JA, Prendergast BM, Jensen LG,  Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study. Am J Clin Oncol 2016;39:8\u201312."},{"key":"B175","series-title":"Int J Radiat Oncol Biol Phys","first-page":"274","article-title":"Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal\/femoral nodes","volume":"63","author":"Chen YJ","year":"2005","unstructured":"Chen YJ, Liu A, Tsai PT,  Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal\/femoral nodes. Int J Radiat Oncol Biol Phys 2005;63:274\u2013281."},{"key":"B176","series-title":"Gastrointest Cancer Res","first-page":"39","article-title":"Intensity-modulated radiation therapy vs 3D conformal radiation therapy for squamous cell carcinoma of the anal canal","volume":"6","author":"Chuong MD","year":"2013","unstructured":"Chuong MD, Freilich JM, Hoffe SE,  Intensity-modulated radiation therapy vs 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res 2013;6:39\u201345."},{"key":"B177","series-title":"Clin Oncol (R Coll Radiol)","first-page":"424","article-title":"Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network","volume":"24","author":"DeFoe SG","year":"2012","unstructured":"DeFoe SG, Beriwal S, Jones H,  Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol (R Coll Radiol) 2012;24:424\u2013431."},{"key":"B178","series-title":"Cancer Invest","first-page":"259","article-title":"Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series","volume":"33","author":"Franco P","year":"2015","unstructured":"Franco P, Mistrangelo M, Arcadipane F,  Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series. Cancer Invest 2015;33:259\u2013266."},{"key":"B179","series-title":"Int J Radiat Oncol Biol Phys","first-page":"153","article-title":"Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy","volume":"82","author":"Kachnic LA","year":"2012","unstructured":"Kachnic LA, Tsai HK, Coen JJ,  Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012;82:153\u2013158."},{"key":"B180","series-title":"Clin Colorectal Cancer","first-page":"716","article-title":"Intensity-modulated radiation therapy for the treatment of anal cancer","volume":"6","author":"Lin A","year":"2007","unstructured":"Lin A, Ben-Josef E. Intensity-modulated radiation therapy for the treatment of anal cancer. Clin Colorectal Cancer 2007;6:716\u2013719."},{"key":"B181","series-title":"Int J Radiat Oncol Biol Phys","first-page":"354","article-title":"Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome","volume":"63","author":"Milano MT","year":"2005","unstructured":"Milano MT, Jani AB, Farrey KJ,  Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005;63:354\u2013361."},{"key":"B182","series-title":"Am J Clin Oncol","first-page":"461","article-title":"Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity","volume":"37","author":"Mitchell MP","year":"2014","unstructured":"Mitchell MP, Abboud M, Eng C,  Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol 2014;37:461\u2013466."},{"key":"B183","series-title":"J Clin Oncol","first-page":"4581","article-title":"Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience","volume":"25","author":"Salama JK","year":"2007","unstructured":"Salama JK, Mell LK, Schomas DA,  Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007;25:4581\u20134586."},{"key":"B184","series-title":"Clin Oncol (R Coll Radiol)","first-page":"700","article-title":"Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions","volume":"27","author":"Yates A","year":"2015","unstructured":"Yates A, Carroll S, Kneebone A,  Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions. Clin Oncol (R Coll Radiol) 2015;27:700\u2013707."},{"key":"B185","series-title":"Cancer","first-page":"3342","article-title":"Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal","volume":"117","author":"Bazan JG","year":"2011","unstructured":"Bazan JG, Hara W, Hsu A,  Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011;117:3342\u20133351."},{"key":"B186","series-title":"Radiother Oncol","first-page":"189","article-title":"Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis","volume":"107","author":"Dasgupta T","year":"2013","unstructured":"Dasgupta T, Rothenstein D, Chou JF,  Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. Radiother Oncol 2013;107:189\u2013194."},{"key":"B187","series-title":"Int J Radiat Oncol Biol Phys","first-page":"27","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic LA","year":"2013","unstructured":"Kachnic LA, Winter KA, Myerson RJ,  RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86:27\u201333."},{"key":"B188","series-title":"Int J Radiat Oncol Biol Phys","first-page":"146","article-title":"Long-term outcomes of NRG Oncology\/RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-c for the reduction of acute morbidity in anal canal cancer","volume":"112","author":"Kachnic LA","year":"2022","unstructured":"Kachnic LA, Winter KA, Myerson RJ,  Long-term outcomes of NRG Oncology\/RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-c for the reduction of acute morbidity in anal canal cancer. Int J Radiat Oncol Biol Phys 2022;112:146\u2013157."},{"key":"B189","series-title":"Adv Radiat Oncol","first-page":"110","article-title":"Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529","volume":"2","author":"Mitra D","year":"2017","unstructured":"Mitra D, Hong TS, Horick N,  Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol 2017;2:110\u2013117."},{"key":"B190","series-title":"J Oncol Pract","first-page":"e992","article-title":"Impact of intensity-modulated radiotherapy on health care costs of patients with anal squamous cell carcinoma","volume":"13","author":"Chin AL","year":"2017","unstructured":"Chin AL, Pollom EL, Qian Y,  Impact of intensity-modulated radiotherapy on health care costs of patients with anal squamous cell carcinoma. J Oncol Pract 2017;13:e992\u20131001."},{"key":"B191","series-title":"Int J Radiat Oncol Biol Phys","first-page":"824","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson RJ","year":"2009","unstructured":"Myerson RJ, Garofalo MC, El Naqa I,  Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824\u2013830."},{"key":"B192","series-title":"Arch Pathol Lab Med","first-page":"1266","article-title":"The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology","volume":"136","author":"Darragh TM","year":"2012","unstructured":"Darragh TM, Colgan TJ, Cox JT,  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012;136:1266\u20131297."},{"key":"B193","series-title":"Dis Colon Rectum","first-page":"1363","article-title":"High-resolution anoscopy surveillance after anal squamous cell carcinoma: high-grade squamous intraepithelial lesion detection and treatment may influence local recurrence","volume":"63","author":"Cappello C","year":"2020","unstructured":"Cappello C, Cuming T, Bowring J,  High-resolution anoscopy surveillance after anal squamous cell carcinoma: high-grade squamous intraepithelial lesion detection and treatment may influence local recurrence. Dis Colon Rectum 2020;63:1363\u20131371."},{"key":"B194","series-title":"Colorectal Dis","first-page":"965","article-title":"Clinicopathological and virological characteristics of superficially invasive squamous-cell carcinoma of the anus","volume":"17","author":"Arana R","year":"2015","unstructured":"Arana R, Fl\u00e9jou JF, Si-Mohamed A,  Clinicopathological and virological characteristics of superficially invasive squamous-cell carcinoma of the anus. Colorectal Dis 2015;17:965\u2013972."},{"key":"B195","series-title":"JAMA Surg","first-page":"209","article-title":"Management of stage I squamous cell carcinoma of the anal canal","volume":"153","author":"Chai CY","year":"2018","unstructured":"Chai CY, Tran Cao HS, Awad S,  Management of stage I squamous cell carcinoma of the anal canal. JAMA Surg 2018;153:209\u2013215."},{"key":"B196","series-title":"AIDS","first-page":"305","article-title":"HAART slows progression to anal cancer in HIV-infected MSM","volume":"29","author":"Duncan KC","year":"2015","unstructured":"Duncan KC, Chan KJ, Chiu CG,  HAART slows progression to anal cancer in HIV-infected MSM. AIDS 2015;29:305\u2013311."},{"key":"B197","series-title":"Dis Colon Rectum","first-page":"1130","article-title":"HIV infection is associated with poor outcomes for patients with anal cancer in the highly active antiretroviral therapy era","volume":"58","author":"Grew D","year":"2015","unstructured":"Grew D, Bitterman D, Leichman CG,  HIV infection is associated with poor outcomes for patients with anal cancer in the highly active antiretroviral therapy era. Dis Colon Rectum 2015;58:1130\u20131136."},{"key":"B198","series-title":"J Clin Oncol","first-page":"2550","article-title":"HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy","volume":"26","author":"Oehler-J\u00e4nne C","year":"2008","unstructured":"Oehler-J\u00e4nne C, Huguet F, Provencher S,  HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008;26:2550\u20132557."},{"key":"B199","series-title":"J Gastrointest Oncol","first-page":"48","article-title":"Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis","volume":"10","author":"Camandaroba MPG","year":"2019","unstructured":"Camandaroba MPG, de Araujo RLC, Silva VS,  Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis. J Gastrointest Oncol 2019;10:48\u201360."},{"key":"B200","series-title":"Eur J Surg Oncol","first-page":"813","article-title":"Surgical excision alone for stage T1 anal verge cancers in people living with HIV","volume":"42","author":"Alfa-Wali M","year":"2016","unstructured":"Alfa-Wali M, Dalla Pria A, Nelson M,  Surgical excision alone for stage T1 anal verge cancers in people living with HIV. Eur J Surg Oncol 2016;42:813\u2013816."},{"key":"B201","series-title":"JAMA Oncol","first-page":"120","article-title":"Association of HIV status with outcomes of anal squamous cell carcinoma in the era of highly active antiretroviral therapy","volume":"4","author":"Bryant AK","year":"2018","unstructured":"Bryant AK, Huynh-Le MP, Simpson DR,  Association of HIV status with outcomes of anal squamous cell carcinoma in the era of highly active antiretroviral therapy. JAMA Oncol 2018;4:120\u2013122."},{"key":"B202","series-title":"J Clin Oncol","first-page":"474","article-title":"Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era","volume":"26","author":"Chiao EY","year":"2008","unstructured":"Chiao EY, Giordano TP, Richardson P,  Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008;26:474\u2013479."},{"key":"B203","series-title":"World J Surg Oncol","first-page":"208","article-title":"Outcomes of abdominoperineal resection for management of anal cancer in HIV-positive patients: a national case review","volume":"14","author":"Leeds IL","year":"2016","unstructured":"Leeds IL, Alturki H, Canner JK,  Outcomes of abdominoperineal resection for management of anal cancer in HIV-positive patients: a national case review. World J Surg Oncol 2016;14:208."},{"key":"B204","series-title":"Clin Oncol (R Coll Radiol)","first-page":"248","article-title":"Are there HIV-specific differences for anal cancer patients treated with standard chemoradiotherapy in the era of combined antiretroviral therapy?","volume":"29","author":"Martin D","year":"2017","unstructured":"Martin D, Balermpas P, Fokas E,  Are there HIV-specific differences for anal cancer patients treated with standard chemoradiotherapy in the era of combined antiretroviral therapy? Clin Oncol (R Coll Radiol) 2017;29:248\u2013255."},{"key":"B205","series-title":"World J Surg","first-page":"876","article-title":"Prognostic and predictive clinicopathologic factors of squamous anal canal cancer in HIV-positive and HIV-negative patients: does HAART influence outcomes?","volume":"42","author":"Pappou EP","year":"2018","unstructured":"Pappou EP, Magruder JT, Fu T,  Prognostic and predictive clinicopathologic factors of squamous anal canal cancer in HIV-positive and HIV-negative patients: does HAART influence outcomes? World J Surg 2018;42:876\u2013883."},{"key":"B206","series-title":"Int J Radiat Oncol Biol Phys","first-page":"143","article-title":"Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients","volume":"75","author":"Seo Y","year":"2009","unstructured":"Seo Y, Kinsella MT, Reynolds HL,  Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys 2009;75:143\u2013149."},{"key":"B207","series-title":"Am J Clin Oncol","first-page":"386","article-title":"Comparison of toxicity and treatment outcomes in HIV-positive versus HIV-negative patients with squamous cell carcinoma of the anal canal","volume":"40","author":"White EC","year":"2017","unstructured":"White EC, Khodayari B, Erickson KT,  Comparison of toxicity and treatment outcomes in HIV-positive versus HIV-negative patients with squamous cell carcinoma of the anal canal. Am J Clin Oncol 2017;40:386\u2013392."},{"key":"B208","series-title":"J Clin Oncol","first-page":"2376","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill AE","year":"2015","unstructured":"Coghill AE, Shiels MS, Suneja G,  Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 2015;33:2376\u20132383."},{"key":"B209","series-title":"Int J Radiat Oncol Biol Phys","first-page":"102","article-title":"Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes","volume":"102","author":"Holliday EB","year":"2018","unstructured":"Holliday EB, Lester SC, Harmsen WS,  Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2018;102:102\u2013108."},{"key":"B210","series-title":"Bull Cancer","first-page":"861","article-title":"[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]","volume":"86","author":"Faivre C","year":"1999","unstructured":"Faivre C, Rougier P, Ducreux M,  [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer 1999;86:861\u2013865 [in French]."},{"key":"B211","series-title":"J Natl Compr Canc Netw","first-page":"355","article-title":"Predictors of nonadherence to NCCN guideline recommendations for the management of stage I anal canal cancer","volume":"15","author":"Kole AJ","year":"2017","unstructured":"Kole AJ, Stahl JM, Park HS,  Predictors of nonadherence to NCCN guideline recommendations for the management of stage I anal canal cancer. J Natl Compr Canc Netw 2017;15:355\u2013362."},{"key":"B212","series-title":"Ann Surg Oncol","first-page":"3934","article-title":"Variation in the use of chemoradiotherapy for stage II and III anal cancer: analysis of the National Cancer Database","volume":"23","author":"Geltzeiler CB","year":"2016","unstructured":"Geltzeiler CB, Tsikitis VL, Kim JS,  Variation in the use of chemoradiotherapy for stage II and III anal cancer: analysis of the National Cancer Database. Ann Surg Oncol 2016;23:3934\u20133940."},{"key":"B213","series-title":"Lancet Oncol","first-page":"347","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Glynne-Jones R","year":"2017","unstructured":"Glynne-Jones R, Sebag-Montefiore D, Meadows HM,  Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol 2017;18:347\u2013356."},{"key":"B214","series-title":"Ann Surg Oncol","first-page":"2780","article-title":"Outcomes of salvage surgery for squamous cell carcinoma of the anal canal","volume":"14","author":"Schiller DE","year":"2007","unstructured":"Schiller DE, Cummings BJ, Rai S,  Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol 2007;14:2780\u20132789."},{"key":"B215","series-title":"Ann Surg Oncol","first-page":"478","article-title":"Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal","volume":"14","author":"Mullen JT","year":"2007","unstructured":"Mullen JT, Rodriguez-Bigas MA, Chang GJ,  Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 2007;14:478\u2013483."},{"key":"B216","series-title":"Int J Radiat Oncol Biol Phys","first-page":"794","article-title":"Predictors and patterns of recurrence after definitive chemoradiation for anal cancer","volume":"68","author":"Das P","year":"2007","unstructured":"Das P, Bhatia S, Eng C,  Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 2007;68:794\u2013800."},{"key":"B217","series-title":"J Clin Oncol","first-page":"3535","article-title":"Cause-specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study","volume":"29","author":"Sunesen KG","year":"2011","unstructured":"Sunesen KG, N\u00f8rgaard M, Lundby L,  Cause-specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study. J Clin Oncol 2011;29:3535\u20133540."},{"key":"B218","series-title":"J Clin Oncol","first-page":"673","article-title":"Definitive organ-sparing treatment of anal canal cancer: can we afford to question it?","volume":"30","author":"Ozsahin M","year":"2012","unstructured":"Ozsahin M, Santa Cruz O, Bouchaab H,  Definitive organ-sparing treatment of anal canal cancer: can we afford to question it? J Clin Oncol 2012;30:673\u2013674; author reply 674\u2013675."},{"key":"B219","series-title":"Cancer","first-page":"405","article-title":"Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment","volume":"86","author":"Allal AS","year":"1999","unstructured":"Allal AS, Laurencet FM, Reymond MA,  Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment. Cancer 1999;86:405\u2013409."},{"key":"B220","series-title":"Oncology","first-page":"183","article-title":"Surgery is an effective option after failure of chemoradiation in cancers of the anal canal and anal margin","volume":"93","author":"Delhorme JB","year":"2017","unstructured":"Delhorme JB, Severac F, Waissi W,  Surgery is an effective option after failure of chemoradiation in cancers of the anal canal and anal margin. Oncology 2017;93:183\u2013190."},{"key":"B221","series-title":"Ann Surg Oncol","first-page":"105","article-title":"Salvage abdominoperineal resection following combined chemotherapy and radiotherapy for epidermoid carcinoma of the anus","volume":"1","author":"Ellenhorn JD","year":"1994","unstructured":"Ellenhorn JD, Enker WE, Quan SH. Salvage abdominoperineal resection following combined chemotherapy and radiotherapy for epidermoid carcinoma of the anus. Ann Surg Oncol 1994;1:105\u2013110."},{"key":"B222","series-title":"Br J Surg","first-page":"1425","article-title":"Salvage abdominoperineal resection in anal epidermoid cancer","volume":"89","author":"Nilsson PJ","year":"2002","unstructured":"Nilsson PJ, Svensson C, Goldman S,  Salvage abdominoperineal resection in anal epidermoid cancer. Br J Surg 2002;89:1425\u20131429."},{"key":"B223","series-title":"Colorectal Dis","first-page":"632","article-title":"A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer","volume":"21","author":"Ko G","year":"2019","unstructured":"Ko G, Sarkaria A, Merchant SJ,  A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer. Colorectal Dis 2019;21:632\u2013650."},{"key":"B224","series-title":"Dis Colon Rectum","first-page":"1090","article-title":"Surgery and high-dose-rate intraoperative radiation therapy for recurrent squamous-cell carcinoma of the anal canal","volume":"54","author":"Wright JL","year":"2011","unstructured":"Wright JL, Gollub MJ, Weiser MR,  Surgery and high-dose-rate intraoperative radiation therapy for recurrent squamous-cell carcinoma of the anal canal. Dis Colon Rectum 2011;54:1090\u20131097."},{"key":"B225","series-title":"Ann Surg Oncol","first-page":"104","article-title":"Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study","volume":"12","author":"Chessin DB","year":"2005","unstructured":"Chessin DB, Hartley J, Cohen AM,  Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol 2005;12:104\u2013110."},{"key":"B226","series-title":"Plast Reconstr Surg","first-page":"1602","article-title":"Primary versus flap closure of perineal defects following oncologic resection: a systematic review and meta-analysis","volume":"137","author":"Devulapalli C","year":"2016","unstructured":"Devulapalli C, Jia Wei AT, DiBiagio JR,  Primary versus flap closure of perineal defects following oncologic resection: a systematic review and meta-analysis. Plast Reconstr Surg 2016;137:1602\u20131613."},{"key":"B227","series-title":"Ann Surg Oncol","first-page":"4186","article-title":"Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence","volume":"19","author":"Lef\u00e8vre JH","year":"2012","unstructured":"Lef\u00e8vre JH, Corte H, Tiret E,  Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. Ann Surg Oncol 2012;19:4186\u20134192."},{"key":"B228","series-title":"Colorectal Dis","first-page":"968","article-title":"Outcome of salvage surgery for anal squamous cell carcinoma","volume":"15","author":"Harris DA","year":"2013","unstructured":"Harris DA, Williamson J, Davies M,  Outcome of salvage surgery for anal squamous cell carcinoma. Colorectal Dis 2013;15:968\u2013973."},{"key":"B229","series-title":"Onkologie","first-page":"5","article-title":"Metastatic anal cancer: the search for cure","volume":"29","author":"Cummings BJ","year":"2006","unstructured":"Cummings BJ. Metastatic anal cancer: the search for cure. Onkologie 2006;29:5\u20136."},{"key":"B230","series-title":"J Natl Compr Canc Netw","first-page":"29","article-title":"Definitive pelvic radiotherapy and survival of patients with newly diagnosed metastatic anal cancer","volume":"17","author":"Wang Y","year":"2019","unstructured":"Wang Y, Yu X, Zhao N,  Definitive pelvic radiotherapy and survival of patients with newly diagnosed metastatic anal cancer. J Natl Compr Canc Netw 2019;17:29\u201337."},{"key":"B231","series-title":"BJS Open","first-page":"zrab060","article-title":"Liver resection and ablation for squamous cell carcinoma liver metastases","volume":"5","author":"Engstrand J","year":"2021","unstructured":"Engstrand J, Abreu de Carvalho LF, Aghayan D,  Liver resection and ablation for squamous cell carcinoma liver metastases. BJS Open 2021;5:zrab060."},{"key":"B232","series-title":"J Clin Oncol","first-page":"2510","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao S","year":"2020","unstructured":"Rao S, Sclafani F, Eng C,  International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. J Clin Oncol 2020;38:2510\u20132518."},{"key":"B233","series-title":"Am J Med","first-page":"221","article-title":"Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal","volume":"87","author":"Ajani JA","year":"1989","unstructured":"Ajani JA, Carrasco CH, Jackson DE,  Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med 1989;87:221\u2013224."},{"key":"B234","series-title":"Oncotarget","first-page":"11133","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume":"5","author":"Eng C","year":"2014","unstructured":"Eng C, Chang GJ, You YN,  The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget 2014;5:11133\u201311142."},{"key":"B235","series-title":"Am J Clin Oncol","first-page":"536","article-title":"Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal","volume":"16","author":"Jaiyesimi IA","year":"1993","unstructured":"Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol 1993;16:536\u2013540."},{"key":"B236","series-title":"Oncology","first-page":"125","article-title":"Carboplatin and paclitaxel treatment is effective in advanced anal cancer","volume":"87","author":"Kim R","year":"2014","unstructured":"Kim R, Byer J, Fulp WJ,  Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology 2014;87:125\u2013132."},{"key":"B237","series-title":"Oncologist","first-page":"402","article-title":"Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients","volume":"22","author":"Sclafani F","year":"2017","unstructured":"Sclafani F, Morano F, Cunningham D,  Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients. Oncologist 2017;22:402\u2013408."},{"key":"B238","series-title":"Clin Colorectal Cancer","first-page":"e39","article-title":"FOLFCIS treatment and genomic correlates of response in advanced anal squamous cell cancer","volume":"18","author":"Mondaca S","year":"2019","unstructured":"Mondaca S, Chatila WK, Bates D,  FOLFCIS treatment and genomic correlates of response in advanced anal squamous cell cancer. Clin Colorectal Cancer 2019;18:e39\u201352."},{"key":"B239","series-title":"Case Rep Oncol","first-page":"249","article-title":"Successful treatment of metastatic anal canal adenocarcinoma with mFOLFOX6 + bevacizumab","volume":"9","author":"Matsunaga M","year":"2016","unstructured":"Matsunaga M, Miwa K, Oka Y,  Successful treatment of metastatic anal canal adenocarcinoma with mFOLFOX6 + bevacizumab. Case Rep Oncol 2016;9:249\u2013254."},{"key":"B240","series-title":"J Clin Oncol","first-page":"394","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer\u2014a GERCOR study","volume":"24","author":"Tournigand C","year":"2006","unstructured":"Tournigand C, Cervantes A, Figer A,  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer\u2014a GERCOR study. J Clin Oncol 2006;24:394\u2013400."},{"key":"B241","series-title":"Lancet Oncol","first-page":"1094","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim S","year":"2018","unstructured":"Kim S, Fran\u00e7ois E, Andr\u00e9 T,  Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol 2018;19:1094\u20131106."},{"key":"B242","series-title":"Ann Oncol","first-page":"3045","article-title":"DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma","volume":"24","author":"Kim S","year":"2013","unstructured":"Kim S, Jary M, Mansi L,  DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol 2013;24:3045\u20133050."},{"key":"B243","article-title":"EA2176: phase 3 clinical trial of carboplatin and paclitaxel +\/\u2212 nivolumab in metastatic anal cancer patients","author":"Eng C","unstructured":"Eng C. EA2176: phase 3 clinical trial of carboplatin and paclitaxel +\/\u2212 nivolumab in metastatic anal cancer patients. ClinicalTrials.gov identifier: NCT04444921. Accessed February 14, 2023. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04444921"},{"key":"B244","article-title":"Carboplatin-paclitaxel with retifanlimab or placebo in participants with locally advanced or metastatic squamous cell anal carcinoma (POD1UM-303\/InterAACT 2)","unstructured":"Incyte Corporation. Carboplatin-paclitaxel with retifanlimab or placebo in participants with locally advanced or metastatic squamous cell anal carcinoma (POD1UM-303\/InterAACT 2). ClinicalTrials.gov identifier: NCT04472429. Accessed February 14, 2023. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04472429"},{"key":"B245","series-title":"Lancet Oncol","first-page":"446","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris VK","year":"2017","unstructured":"Morris VK, Salem ME, Nimeiri H,  Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:446\u2013453."},{"key":"B246","series-title":"Ann Oncol","first-page":"1036","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott PA","year":"2017","unstructured":"Ott PA, Piha-Paul SA, Munster P,  Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017;28:1036\u20131041."},{"key":"B247","series-title":"J Clin Oncol","first-page":"1","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA,  Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1\u201310."},{"key":"B248","series-title":"Lancet Gastroenterol Hepatol","first-page":"446","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle A","year":"2022","unstructured":"Marabelle A, Cassier PA, Fakih M,  Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol 2022;7:446\u2013454."},{"key":"B249","article-title":"Nivolumab with or without ipilimumab in treating patients with refractory metastatic anal canal cancer","author":"Morris VK","unstructured":"Morris VK, Salem ME, Nimeiri H,  Nivolumab with or without ipilimumab in treating patients with refractory metastatic anal canal cancer. ClinicalTrials.gov identifier: NCT02314169. Accessed February 14, 2023. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02314169"},{"key":"B250","series-title":"ESMO Open","first-page":"100529","article-title":"A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao S","year":"2022","unstructured":"Rao S, Anandappa G, Capdevila J,  A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022;7:100529."},{"key":"B251","series-title":"Mol Cancer Res","first-page":"805","article-title":"Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers","volume":"16","author":"Salem ME","year":"2018","unstructured":"Salem ME, Puccini A, Grothey A,  Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol Cancer Res 2018;16:805\u2013812."},{"key":"B252","series-title":"From Cancer Patient to Cancer Survivor: Lost in Transition","year":"2006","unstructured":"Hewitt M, Greenfield S, Stovall E, eds. From Cancer Patient to Cancer Survivor: Lost in Transition. National Academies Press; 2006."},{"key":"B253","series-title":"CA Cancer J Clin","first-page":"428","article-title":"American Cancer Society Colorectal Cancer Survivorship Care Guidelines","volume":"65","author":"El-Shami K","year":"2015","unstructured":"El-Shami K, Oeffinger KC, Erb NL,  American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer J Clin 2015;65:428\u2013455."},{"key":"B254","series-title":"Radiother Oncol","first-page":"55","article-title":"Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort","volume":"108","author":"Bentzen AG","year":"2013","unstructured":"Bentzen AG, Guren MG, Vonen B,  Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. Radiother Oncol 2013;108:55\u201360."},{"key":"B255","series-title":"Pract Radiat Oncol","first-page":"e113","article-title":"Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer","volume":"5","author":"Mirabeau-Beale K","year":"2015","unstructured":"Mirabeau-Beale K, Hong TS, Niemierko A,  Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. Pract Radiat Oncol 2015;5:e113\u2013118."},{"key":"B256","series-title":"Colorectal Dis","first-page":"O230","article-title":"Long-term anorectal, urinary and sexual dysfunction causing distress after radiotherapy for anal cancer: a Danish multicentre cross-sectional questionnaire study","volume":"17","author":"Sunesen KG","year":"2015","unstructured":"Sunesen KG, N\u00f8rgaard M, Lundby L,  Long-term anorectal, urinary and sexual dysfunction causing distress after radiotherapy for anal cancer: a Danish multicentre cross-sectional questionnaire study. Colorectal Dis 2015;17:O230\u2013239."},{"key":"B257","series-title":"Eur J Oncol Nurs","first-page":"479","article-title":"Late effects and quality of life after chemo-radiation for the treatment of anal cancer","volume":"19","author":"Knowles G","year":"2015","unstructured":"Knowles G, Haigh R, McLean C,  Late effects and quality of life after chemo-radiation for the treatment of anal cancer. Eur J Oncol Nurs 2015;19:479\u2013485."},{"key":"B258","series-title":"Int J Colorectal Dis","first-page":"1517","article-title":"Quality of life in patients treated for anal carcinoma\u2014a systematic literature review","volume":"34","author":"Sterner A","year":"2019","unstructured":"Sterner A, Derwinger K, Staff C,  Quality of life in patients treated for anal carcinoma\u2014a systematic literature review. Int J Colorectal Dis 2019;34:1517\u20131528."},{"key":"B259","series-title":"Clin Oncol (R Coll Radiol)","first-page":"530","article-title":"Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors","volume":"16","author":"Jephcott CR","year":"2004","unstructured":"Jephcott CR, Paltiel C, Hay J. Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. Clin Oncol (R Coll Radiol) 2004;16:530\u2013535."},{"key":"B260","series-title":"J Cancer Surviv","first-page":"79","article-title":"Persistent pain in anal cancer survivors","volume":"2","author":"Badin S","year":"2008","unstructured":"Badin S, Iqbal A, Sikder M,  Persistent pain in anal cancer survivors. J Cancer Surviv 2008;2:79\u201383."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/6\/article-p653.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/6\/article-p653.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/6\/article-p653.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T19:46:18Z","timestamp":1686599178000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/6\/article-p653.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":260,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.0030","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}